论文部分内容阅读
目的探讨血小板与淋巴细胞比值(PLR)和中性粒细胞与淋巴细胞比值(NLR)在接受化疗的非小细胞肺癌(NSCLC)患者中对无进展生存时间(PFS)的影响。方法回顾性分析具有完整随访资料的90例患者,均由病理证实为NSCLC,均接受含铂双药方案化疗,应用生存分析,探讨影响PFS的因素。结果在单因素分析中,病理类型、NLR及PLR与中位PFS显著相关。经过COX多元回归模型校正分析,病理类型、转移脏器数目、PLR与不良的预后相关。结论在接受化疗的NSCLC患者中,PLR具有预测PFS的作用,但仍需大样本、前瞻性数据证实本研究结果。
Objective To investigate the effect of platelet to lymphocyte ratio (PLR) and neutrophil to lymphocyte ratio (NLR) on progression-free survival time (PFS) in patients undergoing chemotherapy for non-small cell lung cancer (NSCLC). Methods A total of 90 patients with complete follow-up data were retrospectively analyzed. All of them were confirmed by pathology as NSCLC. All of them were treated with platinum-based chemotherapy. Survival analysis was used to explore the factors influencing PFS. Results In univariate analysis, pathological types, NLR and PLR were significantly associated with median PFS. After COX multiple regression model calibration analysis, pathological type, the number of organs transferred, PLR and poor prognosis. Conclusions In NSCLC patients undergoing chemotherapy, PLR has the potential to predict PFS, but large samples are still needed and prospective data confirm the findings.